Halozyme Therapeutics, Inc. (HALO): EPS (Diluted)
$2.56
Year ended 2025-12-31
+21.1%
3-year compound annual growth
+23.0%
5-year compound annual growth
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.56 | -25.4% | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $3.43 | +63.3% | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | $2.10 | +45.8% | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | $1.44 | -47.4% | 2025-02-18, From 2022-01-01 |
| 2021-12-31 | $2.74 | +201.1% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $0.91 | n/m | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | -$0.50 | n/m | 2022-02-22, From 2019-01-01 |
| 2018-12-31 | -$0.56 | n/m | 2021-02-23, From 2018-01-01 |
| 2017-12-31 | $0.45 | n/m | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | -$0.81 | n/m | 2019-02-21, From 2016-01-01 |
| 2015-12-31 | -$0.25 | n/a | 2018-02-20, From 2015-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.56 | -25.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $1.16 | +152.2% |
| Novavax Inc (NVAX) | 2025-12-31 | $2.58 | n/m |
| Moderna, Inc. (MRNA) | 2025-12-31 | -$7.26 | n/m |
| Qiagen N.V. (QGEN) | 2025-12-31 | $1.94 | +424.3% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $1.21 | n/m |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.78 | +58.0% |
| Repligen Corp (RGEN) | 2025-12-31 | $0.86 | n/m |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $4.67 | +41.9% |
Compare HALO, TECH, NVAX, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗